4D Molecular Therapeutics FDMT Capital investments accrued but not yet paid

Capital investments accrued but not yet paid at other companies

FMC CorporationFMC

$1.9M-80.4%

APO

Apogee EnterprisesAPOG

$3.2M+216%

VestisVSTS

$4.2M—

HTF

Heartflow, Inc. Common StockHTFL

$912K+15,100%

AMC Networks Inc.AMCX

$4.37M+169%

Taboola.com Ltd.TBLA

$617K-67.4%

Other financials

Income statement

See full

Revenue$3.0M+21,664%

Operating income-$73.6M-37.3%

Net income-$68.8M-43.3%

EPS (diluted)-$1.01-17.4%

Balance sheet

See full

Cash & equivalents$72.5M-45.7%

Total debt$20.5M-13.9%

Total equity$451.8M-3.8%

Total assets$512.9M-0.5%

Cash flow

See full

Operating cash flow-$68.1M-42.6%

CapEx--100%

Free cash flow-$68.1M-40.8%

Valuation

See full

Market cap$602.22M+215%

Enterprise value$550.27M+574%

P/S6.8×-8,306×

Profitability

See full

Operating margin-220.1%-110pp

Net margin-174,314.2%-62,763pp

FCF margin-154,209.2%-53,057pp

Returns & leverage

See full

Return on equity-45.4%+29.8pp

Debt / equity0×0.0×

Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CapitalExpendituresIncurredButNotYetPaid.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's capital investments accrued but not yet paid.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is 4D Molecular Therapeutics's capital investments accrued but not yet paid?: 4D Molecular Therapeutics (FDMT) reported capital investments accrued but not yet paid of $0 in Q1 2026.
How has 4D Molecular Therapeutics's capital investments accrued but not yet paid changed year-over-year?: 4D Molecular Therapeutics's capital investments accrued but not yet paid decreased by 100.0% year-over-year, from $140K to $0.